Reps. Charles Boustany (R-LA), Mike Thompson (D-CA), Erik Paulsen (R-MN), John Shimkus (R-IL) and Gene Green (D-CA) introduced the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 3539, on Sept. 17. Championed by IDSA, the READI Act would provide a new 50% tax credit for phase two and three clinical trials (similar to the successful Orphan Drug tax credit) to support the research and development of new antibiotics and antifungal drugs that treat serious or life-threatening infections and address an unmet medical need. The bill also supports R&D of new rapid ID diagnostic tests that provide results in under four hours. IDSA secured broad stakeholder support for the READI Act, including from other medical, scientific, and healthcare provider societies; patient groups; industry; and public health. |
To help READI advance in Congress, we need more representatives to cosponsor this bill. You can help by taking three minutes to email your representative with a request prepared by IDSA through this link.
< Previous Article | Next Article >